Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Yeast-expressed recombinant viral capsid proteins: MerckRecent Research Landscape

Thermal degradation during storage and transport necessitates expensive cold-chain logistics. Engineering the lipid architecture ensures structural integrity and sustained mRNA release at ambient temperatures.

What technical problems is Merck addressing in Yeast-expressed recombinant viral capsid proteins?

Insufficient viral antigen yield

(13)evidences

Biological payloads and delivery vectors lose structural integrity and potency outside of strict cold chain requirements. Overcoming this limitation ensures vaccine efficacy and enables prolonged therapeutic release in vivo.